Lars Blumenstein

1.8k total citations · 1 hit paper
37 papers, 1.3k citations indexed

About

Lars Blumenstein is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lars Blumenstein has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Lars Blumenstein's work include PI3K/AKT/mTOR signaling in cancer (12 papers), Advanced Breast Cancer Therapies (9 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Lars Blumenstein is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (12 papers), Advanced Breast Cancer Therapies (9 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Lars Blumenstein collaborates with scholars based in Germany, United States and Switzerland. Lars Blumenstein's co-authors include Mohammad Reza Ahmadian, Radovan Dvorský, Ingrid R. Vetter, José Baselga, Douglas Bootle, Martin Schüler, Howard A. Burris, Filip Jankú, Marta Gil-Martín and Cornelia Quadt and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Biochemistry.

In The Last Decade

Lars Blumenstein

37 papers receiving 1.3k citations

Hit Papers

Phosphatidylinositol 3-Kinase α–Selective Inhibition With... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Blumenstein Germany 18 944 347 298 184 171 37 1.3k
Sanna Herrgård United States 5 1.3k 1.4× 339 1.0× 113 0.4× 191 1.0× 117 0.7× 6 1.8k
Gabriel Pallares United States 4 1.7k 1.8× 433 1.2× 127 0.4× 186 1.0× 144 0.8× 5 2.4k
Jeremy P. Hunt United States 9 1.8k 2.0× 462 1.3× 130 0.4× 198 1.1× 149 0.9× 10 2.7k
Astrid M. Kral United States 18 2.5k 2.6× 415 1.2× 389 1.3× 106 0.6× 115 0.7× 22 2.9k
Elena Ardini Italy 21 1.0k 1.1× 537 1.5× 343 1.2× 60 0.3× 113 0.7× 38 1.6k
Pingda Ren United States 21 2.3k 2.4× 570 1.6× 216 0.7× 97 0.5× 166 1.0× 49 3.2k
Janis Liebetanz Switzerland 10 976 1.0× 392 1.1× 112 0.4× 79 0.4× 104 0.6× 11 1.6k
Mathew P. Martin United Kingdom 19 1.1k 1.2× 499 1.4× 215 0.7× 118 0.6× 277 1.6× 35 1.6k
J.M. Ostrem United States 6 1.9k 2.0× 818 2.4× 301 1.0× 158 0.9× 210 1.2× 8 2.4k
Lian‐Sheng Li United States 19 1.4k 1.4× 557 1.6× 241 0.8× 89 0.5× 127 0.7× 49 1.9k

Countries citing papers authored by Lars Blumenstein

Since Specialization
Citations

This map shows the geographic impact of Lars Blumenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Blumenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Blumenstein more than expected).

Fields of papers citing papers by Lars Blumenstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Blumenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Blumenstein. The network helps show where Lars Blumenstein may publish in the future.

Co-authorship network of co-authors of Lars Blumenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Blumenstein. A scholar is included among the top collaborators of Lars Blumenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Blumenstein. Lars Blumenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gaze, Mark N., Daria Handkiewicz-Junak, Raquel Hladun, et al.. (2025). Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. European Journal of Nuclear Medicine and Molecular Imaging. 52(11). 4001–4015. 6 indexed citations
2.
Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868. 10 indexed citations
3.
4.
5.
Curigliano, Giuseppe, Miguel Martín, Komal Jhaveri, et al.. (2021). Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer. 151. 49–62. 20 indexed citations
6.
7.
Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →
8.
Juric, Dejan, Filip Jankú, Jordi Rodón, et al.. (2018). Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer. JAMA Oncology. 5(2). e184475–e184475. 186 indexed citations
9.
Rodón, Jordi, Giuseppe Curigliano, Jean‐Pierre Delord, et al.. (2016). A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST). Annals of Oncology. 27. vi119–vi119. 1 indexed citations
10.
Mayer, Ingrid A., Christian F. Singer, Peter A. Fasching, et al.. (2015). A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.. Journal of Clinical Oncology. 1 indexed citations
11.
Blumenstein, Lars, Ulrike Glaenzel, Yi Jin, et al.. (2015). Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemotherapy and Pharmacology. 76(4). 751–760. 30 indexed citations
12.
Schirmer, Eva, Wolfgang Hölzer, Helmut Spreitzer, et al.. (2013). Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives. Bioorganic & Medicinal Chemistry Letters. 23(6). 1846–1852. 4 indexed citations
13.
Barends, Thomas R. M., Tatiana Domratcheva, Lars Blumenstein, et al.. (2008). Structure and Mechanistic Implications of a Tryptophan Synthase Quinonoid Intermediate. ChemBioChem. 9(7). 1024–1028. 46 indexed citations
14.
Casino, Patricia, Dimitri Niks, Huu Ngo, et al.. (2007). Allosteric Regulation of Tryptophan Synthase Channeling:  The Internal Aldimine Probed bytrans-3-Indole-3‘-acrylate Binding. Biochemistry. 46(26). 7728–7739. 10 indexed citations
15.
Fiegen, Dennis, Lars Blumenstein, Ulrike Herbrand, et al.. (2006). Purification and Biochemical Properties of Rac1, 2, 3 and the Splice Variant Rac1b. Methods in enzymology on CD-ROM/Methods in enzymology. 406. 1–11. 22 indexed citations
16.
Blöchl, Andrea, Lars Blumenstein, & Mohammad Reza Ahmadian. (2004). Inactivation and activation of Ras by the neurotrophin receptor p75. European Journal of Neuroscience. 20(9). 2321–2335. 22 indexed citations
17.
Blumenstein, Lars & Mohammad Reza Ahmadian. (2004). Models of the Cooperative Mechanism for Rho Effector Recognition. Journal of Biological Chemistry. 279(51). 53419–53426. 61 indexed citations
18.
Dvorský, Radovan, Lars Blumenstein, Ingrid R. Vetter, & Mohammad Reza Ahmadian. (2004). Structural Insights into the Interaction of ROCKI with the Switch Regions of RhoA. Journal of Biological Chemistry. 279(8). 7098–7104. 116 indexed citations
19.
Blumenstein, Lars, et al.. (2003). Comparative functional analysis of the Rac GTPases. FEBS Letters. 555(3). 556–560. 59 indexed citations
20.
Fiegen, Dennis, Lars Blumenstein, Patricia Stege, Ingrid R. Vetter, & Mohammad Reza Ahmadian. (2002). Crystal structure of Rnd3/RhoE: functional implications1. FEBS Letters. 525(1-3). 100–104. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sanna Herrgård Breakdown of academic impact, for papers by Gabriel Pallares Breakdown of academic impact, for papers by Jeremy P. Hunt Breakdown of academic impact, for papers by Astrid M. Kral Breakdown of academic impact, for papers by Elena Ardini Breakdown of academic impact, for papers by Pingda Ren Breakdown of academic impact, for papers by Janis Liebetanz Breakdown of academic impact, for papers by Mathew P. Martin Breakdown of academic impact, for papers by J.M. Ostrem Breakdown of academic impact, for papers by Lian‐Sheng Li
Rankless by CCL
2026